Annovis Bio Inc (ANVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 42,669 | 45,686 | 47,455 | 49,224 | 5,603 |
| TOTAL | $43,297 | $46,002 | $47,651 | $49,496 | $5,965 |
| Non-Current Assets | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Assets | $43,297 | $46,002 | $47,651 | $49,496 | $5,965 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 929 | 688 | 290 | 115 | 825 |
| Accrued Expenses | 327 | 818 | 831 | 769 | 772 |
| TOTAL | $1,256 | $1,507 | $1,121 | $884 | $1,597 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $1,256 | $1,507 | $1,121 | $884 | $1,597 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 8,164 | 8,164 | 8,101 | 8,101 | 6,947 |
| Common Shares | 1 | 1 | 1 | 1 | 1 |
| Retained earnings | -34,620 | -28,726 | -22,812 | -19,963 | -17,439 |
| TOTAL | $42,040 | $44,495 | $46,530 | $48,612 | $4,368 |
| Total Liabilities And Equity | $43,297 | $46,002 | $47,651 | $49,496 | $5,965 |